Fountain’s $15m will \”restore youthfulness to cells\”
Dr Rando is the founder and chairman at Fountain. He said, \”Fountain represents a biotech firm that has emerged as a result of basic science, in this instance, biology of aging.\” The company’s discovery and screening platform is based on research that shows the environment of the cell can influence the age of the cell. We are identifying compounds which work along these pathways to restore youthful resilience in cells and tissues. This will lead to therapies to treat or prevent chronic diseases associated with aging.
Eli Lilly, R42 Group and Khosla’s biopharma bring the total Series A funding to $26 millions.